ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
15 announcements
Concord Drugs Limited is notifying shareholders about the annual report web-link as per Regulation 36(1)(b). Shareholders are urged to update their email addresses.
Concord Drugs Limited submitted its 31st Annual Report for FY 2025-26 and notice of the 31st Annual General Meeting scheduled for 30th September 2026.
Concord Drugs approved the notice for its 31st AGM on September 30, 2026. The board also finalized director re-appointments and set book closure dates.
Concord Drugs Ltd reported revenue from operations of ₹20.9 Cr (+53.7% YoY) and net profit of ₹1.1 Cr (+1000.0% YoY) for Q1 FY27.
Concord Drugs Limited scheduled a board meeting on August 10, 2026, to consider and approve the unaudited financial results for the quarter ended June 30, 2026.
Concord Drugs Ltd submitted its quarterly shareholding pattern for the period ended June 30, 2026, pursuant to SEBI Regulation 31(1)(b). This is a routine periodic disclosure.
Concord Drugs Ltd filed its quarterly shareholding pattern for the period ended June 30, 2026, as required under SEBI regulations.
Concord Drugs Limited filed its Annual Secretarial Compliance Report for the year ended March 31, 2026. The report notes minor delays in certain regulatory submissions.
Concord Drugs Ltd reported audited consolidated net profit of ₹1.06 Crore for FY26, up from ₹0.34 Crore last year. Revenue significantly increased to ₹78.77 Crore.
Concord Drugs Ltd reported revenue from operations of ₹37.9 Cr (+264.4% YoY) and net profit of ₹0.5 Cr for Q4 FY26.
Concord Drugs Limited approved its audited financial results for the year ended March 2026. Consolidated total revenue surged significantly to ₹78.77 Crore, demonstrating strong performance.
Concord Drugs Ltd scheduled a board meeting for May 27, 2026, to approve audited financial results. The trading window remains closed for designated persons.
Concord Drugs Limited confirmed it does not fall under the 'Large Corporate' category for the financial year ended March 31, 2026. Consequently, the company is not subject to the fund-raising requirements or annual disclosure obligations mandated by SEBI for Large Corporates. The company reported zero outstanding borrowings as of the specified date.
Concord Drugs Limited confirmed it does not qualify as a 'Large Corporate' as of March 31, 2026, under SEBI's debt issuance framework. Consequently, mandatory borrowing requirements through debt securities are not applicable for FY 2025-26.
Concord Drugs Ltd has submitted its initial disclosure under the SEBI Large Corporate framework for the financial year ending March 31, 2026. The company reported outstanding borrowings of ₹10.00 Crore. This filing confirms compliance with debt-raising norms mandated for entities identified as Large Corporates.